Clinical trial
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous…
NCT00309244 · Mannkind Corporation, Industry · Completed
Key facts
| NCT number | NCT00309244 |
|---|---|
| Title | Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up |
| Official title | A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week… |
| Lead sponsor | Mannkind Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Type 2 |
| Intervention type | Drug |
| Interventions | Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) |
| Enrollment | 677 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Mar 31, 2006 |
| Last update posted | Oct 16, 2014 |
| Countries | Argentina, Brazil, Canada, Chile, Mexico, Poland, Russia, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: